Analyst Reco. HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
0.8933 ^USD	+10.82%		+21.87%	+10.28%

25/04	Transcript : HOOKIPA Pharma Inc. - Special Call
25/04	HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on HOOKIPA Pharma to $5 From $6 Amid Restructuring Plan, Termination of Roche Partnership on KRAS; Outperform, Speculative Risk Kept	30/01	MT
HOOKIPA Pharma Says Head, Neck Cancer Phase 2 Study of Therapy Combination Showed 42% Objective Response Rate	23/23/23	MT
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $6.50 From $8, Maintains Buy Rating	11/23/11	MT
Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $2.25 From $2, Maintains Equal-Weight Rating	05/23/05	MT
Truist Securities Adjusts HOOKIPA Pharma Price Target to $4 From $11, Maintains Buy Rating	20/23/20	MT
RBC Trims Price Target on HOOKIPA Pharma to $7 From $8, Affirms Outperform Rating	15/22/15	MT
Truist Securities Lowers HOOKIPA Pharma's Price Target to $11 From $16, Maintains Buy Rating	23/22/23	MT
SVB Securities Adjusts HOOKIPA Pharma's Price Target to $3 From $4, Keeps Outperform Rating	12/22/12	MT
Kempen Upgrades HOOKIPA Pharma to Buy From Neutral, Lifts Price Target to $3 From $2.60	01/22/01	MT
RBC Cuts Price Target on HOOKIPA Pharma to $9 From $11, Maintains Outperform Rating, Speculative Risk Qualifier	25/22/25	MT
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $8 From $15, Maintains Buy Rating	18/22/18	MT
SVB Leerink Adjusts HOOKIPA Pharma's Price Target to $4 from $3, Maintains Outperform Rating	16/22/16	MT
Kempen Downgrades HOOKIPA Pharma to Neutral From Buy, Adjusts Price Target to $2.60 From $24	22/21/22	MT
Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target is $6	12/21/12	MT
HC Wainwright Adjusts Price Target on Hookipa Pharma to $15 From $21, Keeps Buy Rating	11/21/11	MT
SVB Leerink Adjusts HOOKIPA Pharma PT to $10 From $28, Maintains Outperform Rating	11/21/11	MT
JMP Securities Adjusts Price Target on HOOKIPA Pharma to $11 From $25, Maintains Market Outperform Rating	10/21/10	MT
RBC Cuts PT on HOOKIPA Pharma to $17 From $24, Citing Program Prioritization, Timeline Updates; Outperform-Speculative Risk Rating Kept	10/21/10	MT
HOOKIPA PHARMA : Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Maintains Overweight Rating	18/21/18	MT
HOOKIPA PHARMA : HC Wainwright Adjusts HOOKIPA Pharma's Price Target to $21 from $16, Keeps Buy Rating	13/21/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Analyst Reco.

Filters